Sarah Moores, Global Sustainability Director at AstraZeneca, discusses the potential scope for establishing electronic product information (ePI) in the pharmaceutical industry to support its endeavours in environmental sustainability.
The impact of the healthcare sector on the environment is no big secret, but a small change could potentially save half a million trees each year, and significantly reduce its carbon footprint.
As it stands, the production of medicines involves making 100 billion paper medicine information leaflets annually, generating 500,000 tonnes of CO2—equivalent to the annual electricity use of nearly 100,000 homes.1 In the US alone, producing these leaflets requires 41.6 billion litres of water each year, highlighting the significant impact of the existing system on the environment.2 Despite the immense number of resources invested, many paper leaflets go unread, are not understood, and are unnecessarily printed for repeat prescriptions.
Change is needed to enable a greener and more efficient future in this industry. Digital innovation is a critical piece of the response to this challenge, and as part of our ongoing commitment to the environment, AstraZeneca has begun the transition to electronic product information (ePI), with the goal of introducing ePI across all products by 2030.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
ePI allows patients to access product information through web and mobile applications by simply scanning a QR code on the medicine pack. This approach not only ensures that patients receive the most up-to-date information, given information can be updated in real-time, but also significantly reduces the environmental impact associated with paper leaflets.
Sustainable practises in healthcare benefit everyone
ePI represents a step towards reducing the environmental footprint of pharmaceutical supply chains by eliminating paper leaflets and reducing packaging size.
Several AstraZeneca markets have already demonstrated the benefits a transition to ePI could bring. For instance, at the Maihara packing site in Japan, 30 million sheets of paper were saved in just one year following the introduction of ePI.3
If these figures are extrapolated across all AstraZeneca medicines, approximately 500,000 trees, 50,000 tonnes of CO2, and 1.6 billion litres of water could be saved each year.4 Similarly, from an EU perspective, removing paper patient information leaflets (PILs) from all medicine could save 1 Terrawatt hour (TWh) of energy annually, equivalent to the energy consumption of 22 hospital facilities. It could also reduce CO2 emissions by 140kt, which is equivalent to over 100,000 round-trip flights from Paris to New York.6
To ensure these environmental benefits are realised, collaboration between industry, government and healthcare authorities will be essential. Industry and government collaborations, as currently exist in places like South America and Europe, will play a key role in facilitating the widespread adoption of ePI and in ensuring a unified approach to its rollout across regions and markets.
At the Maihara packing site in Japan, 30 million sheets of paper were saved in just one year following the introduction of ePI
With pilot programmes in 24 markets in AstraZeneca, including Japan, Singapore, Australia, Canada, Spain and Portugal, the feasibility and benefits of a transition to ePI are already plain to see—broader adoption across industry is not just a pipe dream. Progress is being made in Europe, where the EU is taking steps to introduce ePI for all medicines and also establish a central system through which ePI can be accessed.2 Similarly in Brazil ePI is allowed in medicines and a paperless pilot is being scoped through collaboration between industry and the Government. Some countries have already fully embraced the transition to digital, for example in Australia where all oral and non-parenteral products now utilise electronic product information.2
However, to ensure these programmes can scale, the public and private sectors must commit to finding long-term solutions that satisfy the needs of patients and healthcare providers.
Maximising impact in a transition to ePI
Beyond its environmental benefits, ePI transforms how patients access and understand product information. By linking to educational sources, using audio and video, and making content searchable, multilingual and easier to read, ePI could enhance how patients learn about and understand their medications, which in turn can help improve health literacy.
Features such as adaptable font sizes and compatibility with existing accessibility software can help empower patients with visual or auditory impairments to play an active role in their care management. Real-time label updates are also made possible by ePI, which means patients can always access the most up-to-date information on their medication, potentially enhancing patient safety.
What must not be overlooked is ensuring that all patients have equitable access to the necessary product information. Any ePI transition must ensure access to product information through alternative means for those who need it, so that those with lower digital literacy, or lack of internet access, are also supported. For example, in Australia, pharmacists can print the product information leaflet upon request.
Overall, the perception of ePI and the use of digital solutions in healthcare is positive. A recent patient study showed that 98 percent of respondents had a positive experience with digital instructions and nearly 80 percent preferred the digital format, underscoring the acceptance and preference for digital solutions among patients.5 While this positive sentiment is encouraging, it is important to remember that ePI will only be a success if patients actually use it, so ensuring they know how to navigate it is critical.
Collaboration with patient communities, pharmacists and healthcare professionals will be necessary to ensure a transition to ePI fulfils its objectives. Since research shows that most patients get their medication information from their physicians or care providers, these healthcare professionals will play a crucial role in educating patients on ePI and encouraging its use.5 Ensuring that appropriate training is provided for healthcare professionals so that they feel supported in their communications on ePI with patients will therefore be essential to its broader success.
If buy-in from both patients and healthcare professionals is achieved, in time ePI can help to facilitate communication with patients, streamline the medication prescription process, and support greater adherence to prescribed medications.
Engaging with patient advocacy groups will also be essential for gaining support and ensuring ePI meets the needs of diverse populations. These groups can advocate for the benefits of ePI, raise awareness and help ensure that the digital solution is accessible and designed with the needs of all target users in mind.
How we set ePI up for future success
Successful implementation requires a unified approach involving all stakeholders to ensure the system is user-friendly, accessible, and meets the needs of diverse populations. By engaging with patient communities, healthcare professionals and advocacy groups, we can ensure that ePI is designed to be inclusive and effective. Continuous engagement with stakeholders and evaluation of its implementation will be crucial to identify areas for improvement and to ensure continued system optimisation. Moreover, fostering a culture of transparency and open communication will help build trust and encourage widespread adoption.
The transition to ePI is not just an environmental imperative but also a step towards creating more efficient and patient-centric healthcare systems. With pilot programmes already demonstrating its feasibility and benefits, broader adoption across the industry is within reach. Together, we can build a robust ePI ecosystem that supports better health outcomes and a healthier planet.
About the author
Sarah Moores is a Global Sustainability Director at AstraZeneca, based in the UK. She has over 20 years of leadership and transformational experience across commercial operations and supply chain. Previously, Sarah served as the operations therapy area lead for the Respiratory and Immunology portfolio, where she led a team accountable for establishing multiple, complex brand-related supply chain strategies. Currently, Sarah leads the AstraZeneca ePI (electronic product information) programme, accelerating the pathway for patients to access digital health information.
Electronic product information (ePI): Securing The Future For Accessible Delivery Of Medicine Information Through Digitalisation. [Internet] Health Policy Partnership. 2024. [Cited 2024Aug]. Available from: https://www.healthpolicypartnership.com/app/uploads/Electronic-product-information-ePI-Securing-the-future-for-accessible-delivery-of-medicine-information-through-digitalisation.pdf
AstraZeneca. Data on File. ID: REF-237703. [Cited 2024Aug].
AstraZeneca. Data on File. ID: REF-222194. [Cited 2024Aug].
Patient Feedback Related to Electronic Product Information (ePI). (Survey conducted on 50 participants. 58% are between the ages of 71 and 70 years of age, and 54% are based in North America). [Cited 2024Jun].
Unpublished Review Analysis By The European Federation Of Pharmaceutical Industries And Associations (EFPIA) And Deloitte. Benefits Case for Electronic Patient Information (ePI).
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.